Healio20h
IBD drug market rattles as Lilly’s Omvoh nabs FDA approval for second IL-23p19 in Crohn’s
The FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease, making it the second ...
Hosted on MSN15h
Omvoh Approved for Crohn's; Fitbit Predicts IBD Flares; H. Pylori and Gastric Cancer
The FDA expanded the approval of mirikizumab (Omvoh) to include treatment of adults with moderately to severely active ...
centerforbiosimilars16h
Biosimilars Drive Cost Savings and Achieve 53% Market Share Across Treatment Areas
Biosimilar launches achieve a 53% market share and a 53% reduction in average drug costs after 5 years of biosimilar ...
Santé log15h
Samsung Bioepis Releases First Quarter 2025 US Biosimilar Market Report
Marks the Third Year Since the Launch of the First US Biosimilar Market Report; INCHEON, South Korea, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. today released it ...